ISSUE FOCUS 72 FEED & ADDITIVE MAGAZINE March 2025 Gonzalo Prat, VP of Sales & Marketing at Axitan: “By focusing conversations on the economic benefits FORC3® could deliver in a healthy flock setting, we saw a fundamental shift in attitude. Discussions were no longer centred around whether CP was or wasn’t a current issue for the producer but around the value FORC3® could potentially deliver. It was a transformational moment that has spawned a swathe of opportunities.” SPECIES EXTENSION Central to these has been the recently announced strategic partnership between Axitan and QualiTech which covers the distribution of FORC3® into new market segments in North America - namely swine, ruminants and poultry, excluding broilers which Axitan continues to market directly. The agreement also sees Axitan and QualiTech collaborating to develop novel endolysin-based products to resolve pathogenic issues in the swine and ruminant segments, QualiTech retaining the exclusive distribution rights of these new products in North America. Scott Hine, President of QualiTech’s Animal Nutrition and Agronomy businesses, was full of praise for what Axitan has achieved to date, “QualiTech is thrilled about the synergies between the Axitan product line and our existing solutions, enabling us to further our strategic focus on early-life vitality and performance, ensuring a strong start and sustained growth. Axitan's proven success with their technology positions them as the ideal development partner for introducing the next generation of performance-enhancing, non-resistance-triggering, antibiotic-free feed additives.” He continued: “With consumer demand increasingly favoring antibiotic-free, high-protein food sources, QualiTech and Axitan are poised to lead the way.” INTERNATIONAL EXPANSION BEYOND NORTH AMERICA And interest in the pioneering work Axitan has done in the feed additives market is extending beyond North America to regions of the world where the declining efficiency of antibiotics to treat common pathogens is being most acutely seen with commercial sales into South Asia having already begun. Dr Miller: “It is a source of immense pride to see a concept, originally born out of UK universities, now being commercially available in two continents. But for the Axitan team, this still very much remains the start of our journey and we remain hugely excited for the future ahead and the ongoing expansion of our product portfolio.”
RkJQdWJsaXNoZXIy MTUxNjkxNQ==